Revisión sistemática

← vista completa

Publicado el 17 de diciembre de 2020 | http://doi.org/10.5867/medwave.2020.11.8078

Terapias celulares para el COVID-19: Una revisión sistemática viva

Cell-based therapies for COVID-19: A living, systematic review

Gabriel Rada , Javiera Corbalán, Patricio Rojas

Este artículo no cuenta con una versión en español.

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Gabriel Rada

radagabriel@epistemonikos.org.

Holanda 895, Providencia, Santiago, Chile

https://orcid.org/0000-0003-2435-0710

Javiera Corbalán

Instituto de Salud Pública, Facultad de Medicina, Universidad Austral de Chile

https://orcid.org/0000-0001-7882-8615

Patricio Rojas

https://orcid.org/0000-0002-5485-3944

Figuras

Artículo no tiene figuras.

Foro

No hay mensajes

Historial

Citación Rada G, Corbalán J, Rojas P. Cell-based therapies for COVID-19: A living, systematic review . Medwave 2020;20(11):e8078 doi: 10.5867/medwave.2020.11.8078

Envío 24/04/2020

Aceptación 16/10/2020

Publicación 17/12/2020

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Palabras claves

COVID-19, severe acute respiratory syndrome coronavirus 2, coronavirus infections, systematic review, cell-based therapies, mesenchymal stem cells, coronavirus disease

Origen y arbitraje

No solicitado . Con revisión externa por tres pares revisores, a doble ciego

Referencias

  1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020. [On line] | Link
  2. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Feb;91:264-266. | CrossRef | PubMed
  3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533-534. | CrossRef | PubMed
  4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. | CrossRef | PubMed
  5. Tavakoli A, Vahdat K, Keshavarz M. Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. BPUMS. 2020;22(6):432-450. | CrossRef
  6. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-583. | CrossRef | PubMed
  7. Global Covid-19 Case Fatality Rates UK: Centre for Evidence-Based Medicine. [On line] | Link
  8. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. | CrossRef | PubMed
  9. Kallmeyer K, Pepper MS. Homing properties of mesenchymal stromal cells. Expert Opin Biol Ther. 2015 Apr;15(4):477-9. | CrossRef | PubMed
  10. Elgaz S, Kuçi Z, Kuçi S, Bönig H, Bader P. Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. Transfus Med Hemother. 2019 Feb;46(1):27-34. | CrossRef | PubMed
  11. Gotts JE, Abbott J, Matthay MA. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. Am J Physiol Lung Cell Mol Physiol. 2014 Sep 1;307(5):L395-406. | CrossRef | PubMed
  12. Shetty AK. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia. Aging Dis. 2020 Mar 9;11(2):462-464. | CrossRef | PubMed
  13. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020 Mar 9;11(2):216-228. | CrossRef | PubMed
  14. Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 2020 Mar;23(2):E71-E83. | PubMed
  15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009 Oct;62(10):1006-12. | CrossRef | PubMed
  16. Rada G, Verdugo-Paiva F, Ávila C, Morel-Marambio M, Bravo-Jeria R, Pesce F, Madrid E, Izcovich A. Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews. Medwave. 2020 Apr 1;20(3):e7868. English, Spanish. | CrossRef | PubMed
  17. Rada G, Corbalan J, Rojas P. Mesenchymal stromal cells for COVID-19: A living systematic review protocol medRxiv 2020.04.13.20064162. | CrossRef
  18. Github repository [Accessed 2020 April 12] [On line] | Link
  19. Epistemonikos Database Methods. Santiago: Epistemonikos Foundation [Accessed 2020 12 April]. [On line] | Link
  20. Methods for the special L·OVE of Coronavirus infection. Santiago: Epistemonikos Foundation [Accessed 2020 12 April] [On line] | Link
  21. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019 Jul;111:105-114. | CrossRef | PubMed
  22. Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, et al. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID). Engineering (Beijing). 2020 Mar 18. | CrossRef | PubMed
  23. COVID-19 Core Outcomes [On line] | Link
  24. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013 Feb;66(2):158-72. | CrossRef | PubMed
  25. Collaboratron [Software]. Santiago: Epistemonikos Foundation, 2017.
  26. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. | CrossRef | PubMed
  27. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. | CrossRef | PubMed
  28. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013 Feb;66(2):173-83. | CrossRef | PubMed
  29. Review Manager (RevMan) [Software]. Version 5.3.5 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
  30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924-6. | CrossRef | PubMed
  31. Borah R, Brown AW, Capers PL, Kaiser KA. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open. 2017 Feb 27;7(2):e012545. | CrossRef | PubMed
  32. Shojania KG, Sampson M, Ansari MT, Ji J Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007 Aug 21;147(4):224-33. | CrossRef | PubMed
  33. Coronavirus and the risks of 'speed science' Reuters; 2020. [On line] | Link
  34. Kelly SE, Moher D, Clifford TJ. Quality of conduct and reporting in rapid reviews: an exploration of compliance with PRISMA and AMSTAR guidelines. Syst Rev. 2016 May 10;5:79. | CrossRef | PubMed
  35. Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017 Nov;91:23-30. | CrossRef | PubMed
  36. Akl EA, Haddaway NR, Rada G, Lotfi T. Future of Evidence Ecosystem Series: Evidence synthesis 2.0: when systematic, scoping, rapid, living, and overviews of reviews come together. J Clin Epidemiol. 2020 Jul;123:162-165. | CrossRef | PubMed
  37. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. J Clin Med. 2020 Feb 26;9(3):623. | CrossRef | PubMed
  38. Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A , Hershan A, Kamal M, et al. Therapeutic Management of COVID-19 Patients: A systematic review. medRxiv. 2020. | CrossRef
  39. Neumann I, Schünemann HJ. Guideline groups should make recommendations even if the evidence is considered insufficient. CMAJ. 2020 Jan 13;192(2):E23-E24. | CrossRef | PubMed
  40. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016 Jun 28;353:i2016. | CrossRef | PubMed
  41. Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 May;26(5):835-844. | CrossRef | PubMed